Related Experiment Video

Updated: Apr 16, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K

Metabolic signature identifies novel targets for drug resistance in multiple myeloma

Patricia Maiso1, Daisy Huynh1, Michele Moschetta1

  • 1Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.

Cancer Research
|March 15, 2015
PubMed

Insights

Altered cell metabolism drives drug resistance in multiple myeloma. Targeting lactate dehydrogenase A (LDHA) and hypoxia-inducible factor 1-alpha (HIF1A) can restore sensitivity to cancer therapies and inhibit tumor growth.

Area of Science:

  • Oncology
  • Cancer Metabolism
  • Molecular Biology

Background:

  • Drug resistance is a significant obstacle in cancer treatment, particularly in multiple myeloma.
  • Minimal residual disease cells contribute to therapy resistance, including to bortezomib and stem cell transplantation.
  • Understanding the mechanisms of drug resistance is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the role of altered tumor cell metabolism in regulating drug resistance in multiple myeloma.
  • To explore the involvement of LDHA and HIF1A in mediating drug resistance.
  • To evaluate the therapeutic potential of targeting LDHA and HIF1A to overcome drug resistance.

Main Methods:

  • Investigated the metabolic phenotype of multiple myeloma cells.
  • Utilized knockdown and gain-of-function studies for LDHA and HIF1A.
  • Assessed the sensitivity of cell lines to bortezomib after manipulating LDHA and HIF1A expression.

Main Results:

  • Altered tumor cell metabolism, specifically through LDHA and HIF1A, plays a key role in multiple myeloma drug resistance.
  • Knockdown of LDHA restored bortezomib sensitivity in resistant cell lines.
  • Overexpression of LDHA or HIF1A induced bortezomib resistance in sensitive cell lines.

Conclusions:

  • HIF1A and LDHA are critical targets for combating hypoxia-driven drug resistance in multiple myeloma.
  • Targeting LDHA and HIF1A can restore sensitivity to therapeutic agents like bortezomib.
  • Novel drugs modulating metabolic pathways, particularly targeting LDHA, hold promise for inhibiting tumor growth and overcoming drug resistance in multiple myeloma.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.3K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
94
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
71